Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
SwitzerlandIPO:
12 February 2020Website:
http://www.addextherapeutics.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | 9 min agoDividend
Analysts recommendations
Institutional Ownership
ADXN Latest News
Addex Therapeutics (ADXN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Addex Therapeutics Ltd (NASDAQ:ADXN ) Q2 2024 Earnings Conference Call September 30, 2024 10:00 AM ET Company Participants Tim Dyer - Co-Founder, Board Director and Chief Executive Officer Misha Kalinichev - Head, Translational Science Conference Call Participants Raghuram Selvaraju - H.C. Wainwright & Co. Operator Good day, and thank you for standing by.
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 19, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its provisional half-year and second quarter net results have increased significantly in 2024 compared to 2023 and first quarter 2024 results primarily due to the sale of part of its business to Neurosterix Pharma Sàrl on April 2, 2024.
Addex Therapeutics Ltd (NASDAQ: ADXN) opened about 70% up this morning after making significant strides in its GABAB-positive allosteric modulator research. The clinical-stage pharmaceutical company has selected candidates for the PAM research that it's undertaking in collaboration with Indivior PLC, as per a press release on Tuesday.
U.S. stocks traded mostly lower midway through trading, with the Dow Jones index falling around 0.2% on Tuesday.
Geneva, Switzerland, July 12, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that Mikhail Kalinichev, Head of Translational Science, will present at the Thirteenth London International Cough Symposium taking place July 18 - 19, 2024 at Imperial College in London, U.K.
● GABAB PAM: Selection of drug candidates under Indivior collaboration expected by end of Q2 2024 .
Geneva, Switzerland, May 31, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it will issue its Q1 2024 Financial Results on June 6, 2024. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.
Addex Therapeutics, a pharmaceutical company focused on allosteric modulation-based drug development, revealed today that CEO Tim Dyer will be speaking at the Swiss Biotech Day 2024 conference held in Basel, Switzerland on April 22 - 23, 2024. The company is listed on the SIX and Nasdaq under the ticker symbol ADXN.
Addex Therapeutics Ltd (NASDAQ: ADXN) will hold its Q4 2023 Earnings Conference Call on April 18, 2024 at 10:00 AM ET. The call will feature Tim Dyer, Chief Executive Officer, and Mikhail Kalinichev, Head of Translational Science. Conference Call Participants include Joanne Lee from Maxim Group, Raghuram Selvaraju from H.C. Wainwright & Co., and Michael Okunewitch from Maxim Group. Operator Good day and thank you for standing by.
- 1(current)
What type of business is Addex Therapeutics Ltd?
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
What sector is Addex Therapeutics Ltd in?
Addex Therapeutics Ltd is in the Healthcare sector
What industry is Addex Therapeutics Ltd in?
Addex Therapeutics Ltd is in the Biotechnology industry
What country is Addex Therapeutics Ltd from?
Addex Therapeutics Ltd is headquartered in Switzerland
When did Addex Therapeutics Ltd go public?
Addex Therapeutics Ltd initial public offering (IPO) was on 12 February 2020
What is Addex Therapeutics Ltd website?
https://www.addextherapeutics.com
Is Addex Therapeutics Ltd in the S&P 500?
No, Addex Therapeutics Ltd is not included in the S&P 500 index
Is Addex Therapeutics Ltd in the NASDAQ 100?
No, Addex Therapeutics Ltd is not included in the NASDAQ 100 index
Is Addex Therapeutics Ltd in the Dow Jones?
No, Addex Therapeutics Ltd is not included in the Dow Jones index
When was Addex Therapeutics Ltd the previous earnings report?
No data
When does Addex Therapeutics Ltd earnings report?
Next earnings report date is not announced yet